Bain Capital Life Sciences Fund L.P. 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 6:55 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund L.P. | 16,915,784 11.000% | 4,713,274 (+38.63%) | Filing |
| 2023-02-14 06:34 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund L.P. | 12,202,510 11.000% | 9,315,968 (+322.74%) | Filing |
| 2022-02-14 06:39 am Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund L.P. | 2,886,542 11.000% | 1,238,057 (+75.10%) | Filing |